Drug Profile
Carbidopa/levodopa controlled release - Indaptus Therapeutics
Alternative Names: Accordion pill carbidopa/levodopa; Accordion Pill levodopa/carbidopa; Accordion Pillcarbidopa/levodopa; AP 09004; AP-CD/LD; AP-CDLD; Carbidopa/levodopa gastric retentive - Indaptus Therapeutics; Levodopa/carbidopa controlled release - Indaptus Therapeutics; Levodopa/carbidopa gastric retentive; Levodopa/carbidopa GRLatest Information Update: 22 Mar 2022
Price :
$50
*
At a glance
- Originator Intec Pharma
- Developer Indaptus Therapeutics
- Class Antiasthmatics; Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
- Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 31 Dec 2021 Discontinued - Phase-III for Parkinson's disease (In the elderly, In adults) in Ukraine, Germany, United Kingdom, Spain, Slovakia, Poland, Italy, Hungary, Bulgaria, Israel, USA (PO)
- 03 Aug 2021 Decoy Biosystems has merged with Intec Pharma to form Indaptus Therapeutics
- 28 Apr 2021 Adverse events data from a phase I and phase II trial in Parkinson's disease released by Intec Pharma